Panmure Gordon reissued their buy rating on shares of Midatech Pharma PLC (LON:MTPH) in a research note published on Thursday. Panmure Gordon currently has a GBX 297 ($3.74) target price on the stock.
Separately, N+1 Singer reiterated a buy rating and issued a GBX 283 ($3.56) target price on shares of Midatech Pharma PLC in a report on Friday, January 20th.
Shares of Midatech Pharma PLC (LON:MTPH) traded up 0.42% during midday trading on Thursday, reaching GBX 120.00. 203,843 shares of the company were exchanged. The company’s 50-day moving average price is GBX 119.47 and its 200 day moving average price is GBX 122.20. Midatech Pharma PLC has a 52-week low of GBX 100.51 and a 52-week high of GBX 189.90. The stock’s market capitalization is GBX 58.44 million.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Ticker Report and is owned by of Ticker Report. If you are reading this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The correct version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/2485631/midatech-pharma-plcs-mtph-buy-rating-reaffirmed-at-panmure-gordon.html.
About Midatech Pharma PLC
Midatech Pharma PLC is an early-stage biopharmaceutical company that focuses on commercializing and developing products in oncology and other therapeutic areas. The Company’s segments include Pipeline Research and Development, and Commercial. The Pipeline Research and Development segment seeks to develop products using the nanomedicine and sustained release technology platforms.
Receive News & Ratings for Midatech Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Midatech Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.